Skip to content

A comparative study of ultrasound-guided microwave ablation and parathyroidectomy in the treatment of primary hyperparathyroidism:A randomized controlled study

A comparative study of ultrasound-guided microwave ablation and parathyroidectomy in the treatment of primary hyperparathyroidism:A randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020680
Enrollment
Unknown
Registered
2019-01-13
Start date
2019-03-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hyperparathyroidism

Interventions

Group 2:Ultrasound-guided Microwave Ablation
Group 2:parathyroidectomy

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Symptomatic patients; 2. Asymptomatic patients with one of the following situations: (1) An increase in serum calcium>0.25 mmol/L above the upper limit of normal; (2) Patients younger than 50 years of age; (3) Patients with a T-score <-2.5 at the lumbar spine, total hip, femoral neck, or distal 1/3 radius or those with a significant reduction in bone mineral density (BMD) and/or increased risk of fragility?fracture; (4) Patients with a reduction in creatinine clearance less than 60 ml/min; (5) Patients who were unable or unwilling to comply with observation protocols; 3.At least one parathyroid nodule clearly showed on US and accessible for MWA; 4.Increased 99 mTc-sestamibi(MIBI) radionuclide concentration in both the early and delayed phases; 5.No recurrent laryngeal nerve impairment confirmed by laryngoscopy in patients with a voice change following previous PTX.

Exclusion criteria

Exclusion criteria: 1. Abnormal coagulation function tests, such as prothrombin time longer than 18 seconds, prothrombin activity lower than 60%, and platelet count less than 60x10^9/L; 2. Intractable complications, such as cardiac insufficiency or hypertension, that could not be controlled with drugs; 3. Negative found on US and 99 mTc-sestamibi.

Design outcomes

Primary

MeasureTime frame
iPTH;Serum calcium;Serum phosphate;ALP;Vitamin D;

Contacts

Public ContactMing'an Yu

China-Japan Friendship Hospital

yma301@163.com+86 15010698109

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026